• >45-60< years of age

• Male sex - Females between STRAW+10 stages -5 and 0 - PMF in STRAW+10 stage +2 - PMF using oral hormone therapy - Females who entered menopause due to a surgical procedure or in response to pharmacotherapy (e.g., gonadotrophin releasing hormone agonists or chemotherapy) - Heart disease such as hypertropic cardiomyopathy, congenital abnormalities, chronic heart failure, valve disease, and a history of myocardial infarction - Medications that impact the central nervous system including selective serotonin reuptake inhibitors, anxiolytics, sedatives, anticholinergic agents, dopamine, amphetamines, or wake-promoting agents (e.g., modafinil). Other medications will be evaluated on an individual basis by the PI. - Cardiovascular medications is also an exclusion criterion which includes those acting on the renin-angiotensin-aldosterone axis, adrenergic receptor antagonists, diuretics, nitrates, and calcium channel antagonists. Other medications will be evaluated on an individual basis by the PI. - Pregnancy - COPD - Diabetes - CKD - Raynaud's phenomenon - Sleep disorders - Shift workers - BMI ≥40.0kg/m2 - Use of nicotine-containing products within the two years preceding study visits - Active cancer treatment